激光原位开窗内移植物修复复杂主动脉弓病变:多中心LIFE登记早期结果
多中心LIFE登记回顾性纳入2017-2022年6个中心82例因主动脉弓病变行TEVAR中激光原位开窗(LIFE)重建弓上分支的患者。技术成功率95.1%,30天死亡率2.4%,卒中率7.4%,36个月生存率94.5%,再干预无生存率78.0%,提示该技术可行且围术期风险与标准技术相当。
要点
- LIFE在复杂主动脉弓TEVAR中技术成功率95.1%,30天死亡率2.4%。
- 早期卒中率7.4%,脊髓缺血率0%,36个月生存率94.5%。
- 36个月再干预无生存率78.0%,中远期耐久性仍需纵向数据验证。
核心结论
- LIFE修复复杂主动脉弓解剖在技术上是可行的,围术期死亡率和神经风险与标准技术相当。
- 尽管早期经验中再干预率中等,但中远期生存率优异,尤其考虑到本队列高危主动脉病理和患者人口学特征。
- 围术期结果和中远期结局仍有前景,但需要纵向数据确认该技术的耐久性。
研究设计与样本
- 回顾性识别2017-2022年6个高容量中心因主动脉弓病变行TEVAR中LIFE的患者,数据收集于多中心LIFE登记。
- 共纳入82例涉及弓上分支的LIFE患者,平均年龄62.4岁,女性29.3%,白人78.0%。
- 采用描述性统计和Kaplan-Meier分析;主要结局为技术成功、卒中和靶血管不稳定,次要结局包括30天死亡率、脊髓缺血和再干预。
主要发现
- TEVAR指征包括B型主动脉夹层70.7%、动脉瘤11.0%、穿透性动脉粥样硬化性溃疡/壁内血肿4.9%;47.9%为非择期手术。
- 技术成功95.1%,30天死亡率2.4%(n=2),早期(<30天)卒中率7.4%、脊髓缺血率0%。
- 平均随访15个月(范围1-81个月)期间额外晚期死亡5例(6.1%);8例(9.8%)在术后平均423±555天(范围17-1479天)接受11次非计划再干预。
- Kaplan-Meier估计36个月生存率94.5%,36个月再干预无生存率78.0%。
临床怎么用
- 对于复杂主动脉弓病变需TEVAR且弓上分支重建的患者,LIFE可作为实现近端锚定的可选技术,尤其适用于0-2区锚定。
- 围术期应关注卒中风险(7.4%),术后需规律随访监测靶血管不稳定和再干预需求。
- 中远期生存率优异但再干预无生存率78.0%,提示需向患者交代再干预可能性并制定长期随访计划。
局限性
- 回顾性研究设计,样本量82例,来自6个高容量中心,存在选择偏倚可能。
- 平均随访仅15个月(范围1-81个月),纵向数据不足,技术耐久性需进一步确认。
- 原文未报告靶血管不稳定具体数据及多变量分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular repair of aortic arch pathologies is limited by currently available device configurations, variation in aortic arch anatomy, access challenges, and frequent nonelective surgical acuity. The present study aims to assess the feasibility and midterm outcomes of laser in situ fenestrated endograft (LIFE) repair for supra-aortic arch branches during thoracic endovascular repair (TEVAR). METHODS: Patients who underwent LIFE during TEVAR for aortic arch pathologies (2017-2022) were retrospectively identified at six high-volume centers, and data were collected in the multicenter LIFE registry. Descriptive statistics and Kaplan-Meier analysis were used. Primary outcomes were technical success, stroke, and target vessel instability. Secondary outcomes included 30-day mortality, spinal cord ischemia, and reinterventions. RESULTS: A total of 82 patients who underwent LIFE with supra-aortic arch involvement were included. The mean age was 62.4 years (29.3% female and 78.0% White). Select demographics of the cohort featured previous stroke in 17.1% of cases, chronic lung disease in 12.2%, and renal insufficiency in 30.5%. Indication(s) for TEVAR included type B aortic dissection in 70.7% of cases, aneurysm in 11.0%, and penetrating atherosclerotic ulcer/intramural hematoma in 4.9%. Repair was performed for nonelective pathologies in 47.9% of cases. Eighty-nine supra-aortic arch branch vessels (innominate, n = 6; left common carotid artery, n = 9; and left subclavian artery, n = 74) were incorporated via LIFE to achieve proximal seal in zone 0 (19%), zone 1 (5%), and zone 2 (75%). LIFE repair was performed for a single-branch vessel in 90% of cases and a double-branch vessel in 10%. Ten patients underwent adjunctive extra-anatomic bypass. Technical success was achieved in 95.1% of cases. Thirty-day mortality was 2.4% (n = 2). Early (<30 days) neurologic outcomes included a stroke and spinal cord ischemia rate of 7.4% and 0%, respectively. At a mean follow-up of 15 months (range, 1-81 months), there were 5 additional late deaths (6.1%). A total of 8 patients (9.8%) required 11 unplanned reinterventions at a mean of 423 ± 555 days (range, 17-1479 days) postoperatively. Kaplan-Meier estimated survival was 94.5% at 36 months, and reintervention-free survival was 78.0% at 36 months. CONCLUSIONS: Results from the multicenter LIFE registry demonstrate laser in situ fenestration of complex aortic arch anatomy to be technically feasible with a perioperative mortality and neurologic risk profile that is comparable to standard techniques. Despite a modest reintervention rate in this early experience, midterm survival is excellent, particularly given the high-risk aortic pathologies and patient demographics featured in this cohort. Although perioperative results and midterm outcomes remain promising, longitudinal data are needed to confirm durability of this technique.
引用
- Ullery BW, Alie-Cusson F, Magee GA, et al. Laser in situ fenestrated endograft (LIFE) repair of complex aortic arch pathology: Early outcomes from the multicenter LIFE registry. J Vasc Surg. 2025. PMID: 41075877. doi:10.1016/j.jvs.2025.09.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。